Program Overview

The 3rd Annual Global Summit on Genitourinary Malignancies focuses on the clinical and practical changes that will occur over the next five years in prostate cancer, renal cell carcinoma and bladder cancer. The program is formatted to foster discussion and debate on the evolution of treatment approaches to genitourinary malignancies featuring didactic lectures, panel discussions and case presentations over individual patient issues and new approaches designed to overcome these challenges.

Presentations will be given by leading experts in the field of genitourinary malignancies, who will offer further insight during question-and-answer sessions. In addition to these leading experts, fellows and junior faculty will have the opportunity to present and discuss their abstracts at an evening poster reception. The Summit assembles translational researchers, clinical researchers, and key community oncologists to address and discuss the challenges of this rapidly developing area of oncology.

Summit Chairs



view all speakers

PEDRO BARATA, MD, MSC


Professor of Urology and Epidemiology & Biostatistics Associate Chair, Clinical Research, Department of Urology


Tulane Cancer Center

New Orleans, LA

pedrobarata

MATTHEW R. COOPERBERG, MD, MPH


Professor of Urology and Epidemiology & Biostatistics Associate Chair, Clinical Research, Department of Urology


Helen Diller Family Chair in Urology University of California, San Francisco

San Francisco, CA

matthewcooperberg

ANNA FERRARI, MD


Professor of Medicine Director, Genitourinary Cancer Program

Rutgers Cancer Institute of New Jersey

New Brunswick, NJ

annaferrari

TERENCE FRIEDLANDER, MD


Associate Professor of Medicine

UCSF Medical Center

San Francisco, CA

terencefriedlander

PETROS GRIVAS, MD, PHD


Associate Professor Clinical Director of Genitourinary Cancers Program

Fred Hutchinson Cancer Research Center University of Washington

Seattle, WA

petrosgrivas

HANS HAMMERS, MD, PHD


Associate Professor

The University of Texas Southwestern

Medical Center
Dallas, TX

Celestia Higano, MD, FACP


Professor of Medicine

University of Washington

Seattle, WA

celestiahigano

Eric Jonasch, MD


Professor of Medicine

University of Texas MD Anderson Cancer Center

Houston, TX

ericjonasch

STACEY KENFIELD, SCD


Associate Professor of Urology Helen Diller Family Chair in Population Science for Urologic Cancer Department of Urology

University of California, San Francisco

San Francisco, CA

staceykenfield.jpg

Joseph Kim, MD


Assistant Professor

Yale University

New Haven, CT

josephkim

VADIM S. KOSHKIN, MD


Assistant Professor

University of California, San Francisco

San Francisco, CA

vadimkoshkin

BENJAMIN MAUGHAN, MD, PHARMD


Assistant Professor, Division of Medical Oncology Huntsman Cancer Institute

Unviersity of Utah

Salt Lake City, UT

benjaminmaughan

ARPIT RAO, MD


ASSISTANT PROFESSOR, DIVISION OF HEMATOLOGY, ONCOLOGY AND TRANSPLANTATION CHAIR, M HEALTH/FAIRVIEW ONCOLOGY QUALITY AND SAFETY COMMITTEE

University of Minnesota Masonic Cancer Center

Minneapolis, MN

arpitrao

ABHISHEK SOLANKI, MD


Assistant Professor Director of Clinical Research & Quality Medical Director Department of Radiation Oncology

Stritch School of Medicine, Loyola University

Maywood, IL

abhisheksolanki

SRIKALA SRIDHAR, MD, MSC, FRCPC


Associate Professor

Princess Margaret Cancer Center

Toronto, Ontario, Canada

srikalasridhar

WALTER STADLER, MD


Fred C. Buffet Professor of Medicine and Surgery Chief, Section of Hematology/Oncology Deputy Director, Comprehensive Cancer Center

The University of Chicago Medicine

Chicago, IL

walterstadler

Nizar M. Tannir, MD, FACP


Professor and Chair ad interim Ransom Horne, Jr. Professor in Cancer Research Department of Genitourinary Medical Oncology Division of Cancer Medicine

UT MD Anderson Cancer Center

Houston, TX

nizartannir


Hamid Emamekhoo, MD


Assistant Professor

University of Wisconsin Carbone Cancer Center University of Wisconsin School of Medicine and Public Health

Madison, WI

Rohit Jain, MD, MPH


Assistant Member, Department of Genitourinary Oncology Moffitt Cancer Center

Tampa, FL

ANIL KAPOOR, MD, FRCSC


Chair, Kidney Cancer Research Network of Canada Director, Urologic Cancer Centre for Research & Innovation
Chair, Genito-Urinary Oncology Program Juravinski Cancer Centre
Professor of Surgery (Urology) and Oncology


McMaster University Hamilton,

Ontario, Canada

DEEPAK KILARI, MD


Assistant Professor

Medical College of Wisconsin

Milwaukee, WI

William Tester, MD, FACP


Clinical Professor of Medical Oncology Medical Director of Outpatient Operations Jefferson Sidney Kimmel Cancer Center Thomas Jefferson University

Philadelphia, PA

Ulka Vaishampayan, MD


Chair, Division of Solid Tumor Oncology Director of Phase I Therapeutics Karmanos Cancer Institute Charles Martin Endowed Chair Professor of Oncology

Wayne State University

Detroit, MI

Alexander Wyatt, PhD


Senior Research Scientist Vancouver Prostate Centre Assistant Professor, Department of Urologic Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Haris Zahoor, MD


Assistant Professor of Clinical Medicine Keck School of Medicine

University of Southern California

Los Angeles, CA

Summit Agenda

Download Schedule
  • 5:45 PM Welcome and Introductions

  • Keynote Address

    6:00 PM GU Malignancies: Perspectives and a Peer Into the Future

  • Setting The Stage

    6:30 PM What are the Practice Changes in 2019 for Advanced Prostate Cancer?

    6:45 PMWhat are the Practice Changes in 2019 for Metastatic RCC?

    7:00 PM What are the Practice Changes in 2019 for Bladder Cancer?

    7:15 PM Moving Forward with Immunotherapy in GU Malignancies

    7:30 PM The Era of Personalized Therapy for GU Tumors

    7:45 PMDISCUSSION

    8:00 PMADJOURN TO WELCOME RECEPTION

  • 5:45 PM Welcome and Introductions

  • Keynote Address

    6:00 PM GU Malignancies: Perspectives and a Peer Into the Future

  • Setting The Stage

    6:30 PM What are the Practice Changes in 2019 for Advanced Prostate Cancer?

    6:45 PMWhat are the Practice Changes in 2019 for Metastatic RCC?

    7:00 PM What are the Practice Changes in 2019 for Bladder Cancer?

    7:15 PM Moving Forward with Immunotherapy in GU Malignancies

    7:30 PM The Era of Personalized Therapy for GU Tumors

    7:45 PMDISCUSSION

    8:00 PMADJOURN TO WELCOME RECEPTION

  • 6:00 AM Breakfast

  • Advances In Imaging And Diagnosis

    7:00 AM Blue Light Flexible Cystoscopy for Surveillance of Bladder Cancer

    7:15 AM PET Imaging in Prostate Cancer

    7:30 AM Challenges with RCC Type 1 and Type 2 Pathology Diagnosis

    7:45 AM Subtyping RCC on Imaging - The Role of Radiologist

    8:00 AM Modeling Cost Effectiveness of Biomarker Based Approaches to Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer

    8:15 AM Emerging Agent Showcase

    8:30 AM DISCUSSION

  • The Role Of Surgery In GU Malignancies

    9:00 AM Optimal Timing for Radical Cystectomy After Neoadjuvant Chemotherapy

    9:15 AM Radical Prostatectomy in Metastatic Disease

    9:30 AM DISCUSSION

    10:00 AM BREAK

  • Immunotherapy In GU Malignancies

    10:15 AM Maximizing Clinical Response to Immune Checkpoint Therapy in GU Malignancies

    10:30 AM Current Data and Future Trials for PD-1/PD-L1 Inhibitors for Bladder Cancer

    10:45 AM Is There a Future for Immunotherapy in Prostate Cancer?

    11:15 AM Emerging Agent Showcase

    11:30 AM DISCUSSION AND CASE STUDIES

    12:00 PM ADJOURN

    <
  • Current Understanding Of TKI In RCC

    5:00 PM How do we Optimize the Effectiveness of VEGF Inhibitors?

    5:15 PM The Role of Sequencing in TKIs

    5:30 PMDISCUSSION

  • The Spectrum Of Metastatic Disease In Prostate Cancer

    5:45 PM Management of Metastatic Castrate-sensitive Prostate Cancer

    6:00 PM Does Treating the Primary Make a Difference in Metastatic Disease?

    6:15 PMDISCUSSION

  • Learning From Genomics And Biomarkers

    6:30 PM Emerging Biomarkers and Imaging Tests to Improve Prostate Cancer Diagnostics

    6:45 PM Genetic Heterogeneity in Kidney Cancer

    7:00 PMGenomic Classification in Localized Disease: How Can It Improve Outcomes?

    7:15 PM Molecular Landscape of Non-muscle Invasive Versus Muscle Invasive Bladder Cancer

    7:30 PM Utilizing Genomics for the Selection of Systemic Therapy

    7:45 PM DISCUSSION

    8:15 PM ADJOURN

  • 6:00 AM Breakfast

  • Targeted Therapy In Bladder Cancer

    7:00 AM Targeting FGFR and mTOR in Bladder Cancer

    7:15 AM Targeting DNA Repair Genes in Bladder Cancer

    7:30 AM Taking Advantage of Nectin-4 Expression in Bladder Cancer with ADCs

    7:45 AM Updates in Management of Urothelial Cancer

    8:00 AM DISCUSSION

  • Bladder Preservation Therapy

    8:15 AM Match Pair Analysis of Cystectomy Compared to Tri-modality Therapy

    8:30 AM Curative Treatments of Invasive Bladder Cancer Using Combined Modality Therapy

    9:00 AM Combining Immunotherapy and Radiation Therapy in Bladder Cancer

    9:15 AM DISCUSSION

  • Targeting AR In CRPC: A Major Therapeutic Challenge

    9:30 AMAR Agents in Non-metastatic CRPC

    9:45 AMBiologic Rationale for Next-generation AR Inhibitors

    10:00 AMApproaches to Block Persistent AR Function in Metastatic CRPC

    10:15 AMAn Androgen Receptor PROTAC Degrader for Prostate Cancer

    10:30 AMDISCUSSION

    10:45 AMBREAK

  • Moving Beyond Hormone Receptors In Prostate Cancer

    10:55 AM PARP Inhibitors in Prostate Cancer

    11:10 AM Alterations in AR Signaling in Prostate Cancer Development and Progression

    11:25 AM CDK4/6 Inhibition as Novel Therapeutic Strategy for Metastatic Prostate Cancer

    11:40 AM Emerging Agent Showcase

    11:55 AM DISCUSSION AND CASE STUDIES

    12:30 PM ADJOURN

  • Quality Of Life And Outcome Considerations For Gu Malignancies

    5:00 PMHow Can PRO Drive Drug Development and Standards of Care?

    5:15 PM Emerging Quality of Life Trends with Early Use of Novel Antiandrogen Therapies in Advanced Prostate Cancer

    5:30 PMEmerging Quality of Life Trends with Early Use of Novel Antiandrogen Therapies in Advanced Prostate Cancer

    5:45 PMIntegrating Lifestyle Changes and Exercise into Prostate Cancer Care

    6:00 PMDISCUSSION

  • Combination Approaches For Immunotherapy

    6:15 PMCombination Therapy Targeting CTLA-4 and PD-1/PD-L1: Risks and Benefits for RCC

    6:30 PMImmunotherapy Combination Approaches with Chemotherapy and Targeted Therapies in Bladder Cancer

    6:45 PMEmerging Agent Showcase

    7:00 PM Emerging Agent Showcase

    7:15 PMDISCUSSION

    Practical Considerations For Immunotherapy

    7:30 PMManaging Immunotherapy Toxicity in Bladder Cancer

    7:45 PMTreatment After Checkpoint Therapy, What Do We Do Post Immunotherapy?

    8:00 PMDISCUSSION

    8:15 PMADJOURN

  • Oral Abstracts

    7:00 AMOral Abstract 1

    7:15 AM Oral Abstract 2

    7:30 AMOral Abstract 3

    7:45 AMOral Abstract 4

    8:00 AMOral Abstract 5

    8:15 AMOral Abstract 6

    8:30 AMMEETING CONCLUDES

Attendance Benefits

  • Networking opportunities with GU oncology leaders
  • Post-meeting access to video presentations
  • Participate in discussion and debate surrounding the field of GU oncology
  • Daily breakfast, evening receptions with refreshments


Travel Details

North America Map
banff fairmont hotel

Hotel

  • The 3rd Annual Global Summit on Genitourinary Malignancies will be held at
             the Fairmont Chateau Banff Springs
  • OMI room block rate: 303 CAD/night
  • Room block closing date: September 9, 2019

Transfer

  • Transfer time between YYC and the Fairmont Banff Springs: 2 hours
  • OMI recommends using the Banff Airporter for transfer at a 20% discounted
             rate with promo code “OMI”
  • Discounted rate: 114 CAD/person (roundtrip)

Fall Activities in Banff

  • Scenic hiking
  • Gondala rides
  • Biking
  • Village shopping
  • Tour Lake Louise
  • Wildlife tours
  • Horseback riding

Dava Oncology – three divisions, one focus

dava oncology logo
omi logo
one-oncology logo

Contact Us